Product Description
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T. Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo. Smaller number of 4th generation GPC3 CAR-T required than other groups to remove HCC. (Sourced from: http://www.eutilex.com/en/sub3/sub1_view.php?idx=8)
Mechanisms of Action: CAR-T,GPC3,IL18
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eutilex
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for EU-307](https://pryzm-maps.s3.us-west-2.amazonaws.com/169current_maps.png)
Countries in Clinic: Korea
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EU-CTS307-I-01 | P1 |
Recruiting |
Hepatocellular Carcinoma |
2025-06-01 |
44% |